Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
Joseph E. Ebinger, Justyna Fert‐Bober, Ignat Printsev, Min Wu, Nancy Sun, John C. Prostko, Edwin C. Frias, James L. Stewart, Jennifer E. Van Eyk, Jonathan Braun, Susan Cheng, Kimia Sobhani
Abstract
In a cohort of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Topics & Concepts
AntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineAntibody responseSpike ProteinCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakImmunologyMessenger RNABiologyInternal medicineOutbreakGeneDiseaseInfectious disease (medical specialty)BiochemistrySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral Infections and Immunology Research